In the days before the term “high-grade undifferentiated pleomorphic sarcoma” came into use, one of the most common sarcoma diagnoses was “malignant fibrous histiocytoma,” and before that, in an era before immunohistochemistry, “fibrosarcoma” was used to describe most sarcomas. “Spindle cell” is a descriptive phrase that denotes the cellular shape of many of the sarcomas encountered in the adult population. As a result, they are usually treated differently from small round cell sarcomas, and have different biological characteristics than those tumors and sarcomas with epithelioid morphology. As a very broad generalization, sarcomas with a spindle cell microscopic morphology occur in adults and are treated primarily with surgery and often adjuvant or neoadjuvant radiation as primary therapy. In comparison to small round cell sarcomas such as Ewing sarcoma, the use of adjuvant chemotherapy remains controversial, and the sensitivity of these tumors to chemotherapy in the metastatic setting is highly variable. In this article, we describe some of the clinical and biological characteristics of this group of sarcomas.
aDepartment of Anatomic Pathology, IRCCS Foundation, Istituto Nazionale Tumori, Milan, Italy
bDepartment of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada
cSarcoma Center, Department of Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
dCentre Leon Berard, Hôpital Edouard Herriot, pav. E and INSERM U590, Lyon, France
eUniversity Hospital Medical Center Grosshadern, Medical Clinic III, Munich, Germany; and HelmholtzZentrum München, German Research Center for Environmental Health, CCG Hyperthermia, Neuherberg, Germany
fSarcoma Program, Memorial Sloan-Kettering Cancer Center, New York, NY
gDepartment of Oncology, University Hospital, Lund, Sweden
Address correspondence to Xavier Garcia del Muro, MD, Instituto Catalán de Oncología, c/Viladomat 319 Atico 1, Barcelona 08029, Spain
Jean-Yves Blay is supported by CONTICANET Network of Excellence of the 6th FP of the European Commission; Poul H.B. Sorensen has received grants from the Canadian Institutes for Health Research; and Robert G. Maki is supported by Program Project Grant No. P01-CA47179; Cycle for Survival.
DisclosuresJean-Yves Blay: Research support, consulting fees (Pfizer, Novartis, Roche, Glaxo Smith Kline)
Robert G. Maki: Research support (Pfizer); honoraria (Ziopharm); testimony (Roche)
1,2 These authors contributed equally to this work.